|Title:|| Methods for administration of taxol|
|Abstract:||Taxol dosages of about 135 mg/m.sup.2 or greater are administered via infusions of less than 6 hours duration; the method makes it possible to provide taxol infusions on an out-patient basis to patients who do not otherwise require hospitalization. In a preferred embodiment, about 135 mg/m.sup.2 of taxol in a cremaphor emulsion is infused over a 3 hour duration, following patient pretreatment with steroids, antihistamines, and H.sub.2 -receptor antagonists sufficient to prevent fatal anaphylactic-like reactions, and preferably sufficient to reduce the occurrence of severe anaphylactic-like reactions in greater than 90% of patients treated. In an alternative embodiment, between 135 mg/m.sup.2 and about 175 mg/m.sup.2 of taxol is provided in a 3-hour infusion, following pretreatment to minimize hypersensitivity responses. A method for rechallenging patients with taxol after episodes of acute hypersensitivity reactions is also disclosed, thus enabling patients to continue taxol therapy who would otherwise be deprived of treatment.|
|Inventor(s):|| Canetta; Renzo M. (Madison, CT), Eisenhauer; Elizabeth (Kingston, CA), Rozencweig; Marcel (Brandford, CT) |
|Assignee:|| Bristol-Myers Squibb Company (New York, NY) |
|Filing Date:||Nov 20, 1995|
|Claims:||1. A method for reducing peripheral neurotoxicity symptoms in patients suffering from ovarian cancer and undergoing TAXOL therapy comprising reducing peripheral neurotoxicity symptoms in said patients while maintaining an antitumor effect by administering about 135 mg/m.sup.2 over a period of about 24 hours. |
2. The method of claim 1 wherein the administration of taxol is repeated at least once, about 21 days after the preceding administration.